S

    Spyre Therapeutics Inc. (SYRE)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $90.36
    -3.25 (-3.48%)

    Market Cap: $7.85B

    Last updated: Sep 01, 2026 at 10:00 AM ET

    Earnings

    Performance (10Y)

    Beat Rate
    40%(16/40)
    Avg Surprise
    -455.76%
    Streak
    1 Q

    Upcoming Estimates

    Sep 30, 2026
    EPS Consensus$-0.81
    Range$-1.53 - $-0.53
    13 analysts
    EPS Revisions
    2
    0
    7d
    2
    5
    30d
    EPS Estimate Drift
    90d ago$-0.69+14.4%
    60d ago$-0.73+10.4%
    30d ago$-0.73+10.4%
    7d ago$-0.81+0.2%
    Current$-0.81
    Revenue Consensus
    $0
    Range$0 - $0
    12 analysts
    Dec 31, 2026
    EPS Consensus$-0.62
    Range$-2.60 - $0.02
    13 analysts
    Revenue Consensus
    $0
    Range$0 - $0
    12 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$-0.62---
    Sep 26EST
    		-$-0.81---
    Jun 26
    		$-0.36$-0.71+49.30%Beat+26.5%
    Mar 26
    		$-0.74$-0.64-14.84%Miss-23.3%
    Dec 25
    		$-0.74$-0.80+7.50%Beat+8.6%
    Sep 25
    		$-0.15N/A+79.73%Beat+89.0%
    Jun 25
    		$-0.49$-0.71+30.99%Beat+43.0%
    Mar 25
    		$-0.60$-0.84+28.57%Beat+50.0%
    Dec 24
    		$-0.81$-0.94+14.22%Beat+80.0%
    Sep 24
    		$-1.36$-0.86-58.14%Miss+85.4%
    Jun 24
    		$-0.86$-0.91+5.49%Beat+98.5%
    Mar 24
    		$-1.20$-1.08-11.11%Miss+76.0%
    Dec 23
    		$-4.05$-0.78-419.23%Miss+19.0%
    Sep 23
    		$-9.34$-0.84-1011.90%Miss-96.6%
    Jun 23
    		$-56.75$-3.50-1521.43%Miss-740.7%
    Mar 23
    		$-5.00$-4.37-14.42%Miss+45.9%
    Dec 22
    		$-5.00$-0.23-2090.10%Miss+35.5%
    Sep 22
    		$-4.75$-5.87+19.08%Beat+38.7%
    Jun 22
    		$-6.75$-7.75+12.90%Beat-170.0%
    Mar 22
    		$-9.25$-0.34-2609.43%Miss-32.1%
    Dec 21
    		$-7.75$-7.63-1.57%Miss+11.4%
    Sep 21
    		$-7.75$-7.34-5.59%Miss-6.9%
    Jun 21
    		$-2.50$-4.30+41.86%Beat+75.0%
    Mar 21
    		$-7.00$-3.49-100.57%Miss+50.9%
    Dec 20
    		$-8.75$-0.34-2451.76%Miss+46.2%
    Sep 20
    		$-7.25$-9.97+27.28%Beat+56.1%
    Jun 20
    		$-10.00$-10.76+7.06%Beat+27.3%
    Mar 20
    		$-14.25$-16.41+13.16%Beat+3.4%
    Dec 19
    		$-16.25$-0.67-2325.37%Miss-4.8%
    Sep 19
    		$-16.50$-13.31-23.97%Miss-22.2%
    Jun 19
    		$-13.75$-12.08-13.82%Miss-19.6%
    Mar 19
    		$-14.75$-13.80-6.88%Miss-20.4%
    Dec 18
    		$-15.50$-0.37-4089.19%Miss-59.0%
    Sep 18
    		$-13.50$-10.80-25.00%Miss-12.5%
    Jun 18
    		$-11.50$-8.62-33.41%Miss+2.1%
    Mar 18
    		$-12.25$-11.51-6.43%Miss-4.3%
    Dec 17
    		$-9.75$-0.53-1739.62%Miss-1641.1%
    Sep 17
    		$-12.00$-13.77+12.85%Beat-2.1%
    Jun 17
    		$-11.75$-12.00+2.08%Beat-
    Mar 17
    		$-11.75$-11.70-0.43%Miss-
    Dec 16
    		$-0.56$-0.46-21.74%Miss-
    Sep 16
    		$-11.75$-13.59+13.54%Beat-

    Key Metrics

    Valuation
    P/E Ratio-45.41EV/EBITDA-7.96x
    Price/FCF-36.80xFCF Yield-2.72%
    Profitability
    Profit Margin0.00%Operating Margin0.00%
    ROE-23.00%ROICN/A
    Financial Health
    Debt/EquityN/AInterest CoverageN/A
    Current Ratio18.53xQuick Ratio18.53x
    Trading Statistics
    Beta3.03Avg Volume945.71K
    52-Week High$110.1752-Week Low$14.51

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$102.72
    SMA 20$102.87
    SMA 50$98.47
    SMA 200$60.37
    EMA 10$99.85
    EMA 20$101.06
    EMA 50$96.32
    EMA 200$67.39

    MACD

    Line: -0.21Signal: 1.88Hist: -2.09

    ADX

    ADX: 17.3+DI: 15.1-DI: 30.3

    Aroon & PSAR

    Aroon Up72.0
    Aroon Down100.0
    PSAR$109.40

    Bollinger Bands

    Upper Band$113.60
    Lower Band$92.14
    %B Position2086%(Upper)
    Band Width-0.08

    RSI (14-Day)

    Neutral
    35.6

    Momentum Oscillators

    Stoch %K11.7
    Stoch %D35.4
    Williams %R-95.6
    ROC (10d)-12.8%
    Momentum-13.27
    CCI (20d)-199.5
    MFI (14d)41.8

    Volatility Measures

    ATR (14d)$5.81(6.4%)
    StdDev (20d)5.37
    Hist Vol66.2%(High)

    Volume Flow

    VWAP$91.07
    OBV42.9M
    AD Line14.4M
    CMF (20d)0.126

    Volume Metrics

    Avg Vol (20d)966.6K
    Vol Ratio1.3x
    VWMA (20d)$101.41

    Pivot Points

    R3$98.98
    R2$96.97
    R1$95.29
    Pivot Point$93.27
    S1$91.59
    S2$89.58
    S3$87.90

    Advanced Oscillators

    TSI-0.68
    Ultimate Osc41.9
    KST52.98

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$0$0$90.49M$0$0$0$0$0$0$0$1.04M$0
    Cost of Revenue$0$0$45.25M$0$0$0N/A$0$0$0$964,000$0
    Gross Profit$0$0$45.25M$0$0$0N/A$0$0$0$78,000$0
    Operating Expenses$41.64M$45.64M$57.17M$56.89M$41.94M$53.57M$61.25M$55.39M$44.15M$47.77M$45.91M$18.34M
    R&D$65.50M$60.41M$44.64M$45.25M$40.15M$41.62M$50.48M$44.74M$32.64M$34.93M$33.68M$24.36M
    SG&A$16.14M$15.23M$12.53M$11.64M$11.79M$11.94M$10.77M$10.65M$11.51M$12.85M$14.07M$8.58M
    Operating Income$-41,639,000$-45,641,000$-57,172,000$-56,888,000$-41,935,000$-53,567,000$-61,253,000$-55,392,000$-44,147,000$-47,774,000$-45,914,000$-18,337,000
    Interest Income$10.05M$7.00M$7.14M$5.38M$5.87M$6.49M$5.78M$5.18M$5.92M$4.43M$4.13M$1.25M
    Interest Expense$0$23.36M$5.36M$0$0$0$0$13.62M$0$0$17.27M$21.77M
    Income Before Tax$-36,200,000$-69,005,000$-62,530,000$-11,183,000$-36,717,000$-44,788,000$-56,295,000$-69,010,000$-38,837,000$-43,825,000$-63,180,000$-40,104,000
    Income Tax Expense$0$0$0$0$0$-15,000$1,000$18,000$0$32,000$0$3,000
    Net Income$-36,200,000$-69,005,000$-62,530,000$-11,183,000$-36,717,000$-44,773,000$-56,296,000$-69,028,000$-38,837,000$-43,857,000$-63,180,000$-40,107,000
    EBITDA$-49,346,000$-78,059,000$-71,754,000$-17,912,000$-44,604,000$-53,923,000$-64,490,000$-77,195,000$-48,318,000$-50,680,000$-69,012,000$-41,844,000
    EBIT$-46,253,000$-76,000,000$-69,669,000$-16,562,000$-42,591,000$-51,281,000$-62,071,000$-74,194,000$-44,757,000$-48,257,000$-67,306,000$-41,355,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about SYRE

    News

    SYRE Maintained by Wedbush -- Price Target Lowered to $123.00

    Wedbush maintained an "Outperform" rating for Spyre Therapeutics Inc (SYRE) but lowered its price target from $130.00 to $123.00, reflecting a cautious outlook. The company has a low GF Score™ of 26/100, indicating weaknesses in profitability and growth, and has seen significant insider selling despite its strong financial strength. Investors are advised to be cautious due to the high valuation and insider activity.

    GuruFocus•8/26/26•
    Somewhat-Bearish

    Deutsche Bank Adjusts Spyre Therapeutics PT to $127 From $135, Maintains Buy Rating

    Deutsche Bank has adjusted its price target for Spyre Therapeutics (SYRE) to $127, down from $135, while reiterating a Buy rating on the stock. This update reflects a revised valuation by the bank. Meanwhile, Wedbush also adjusted its price target for Spyre Therapeutics to $123 from $130, maintaining an Outperform rating.

    marketscreener.com•8/26/26•
    Neutral

    S&P 500 Futures Flat in Premarket Trading; Spyre Therapeutics, Intuit Lag

    S&P 500 futures were trading flat in premarket activity. Meanwhile, Spyre Therapeutics and Intuit were lagging, while Summit Therapeutics Inc. (SMMT) and J.M. Smucker Co. (SJM) showed gains. Summit Therapeutics was up 8.3% and J.M. Smucker Co. was up 5.2% in pre-market trading.

    Barron's•8/26/26•
    Neutral

    Spyre Therapeutics (NASDAQ:SYRE): Why Is It in Focus After It reported topline results from a rheumatoid-arthritis substudy?

    Spyre Therapeutics (NASDAQ:SYRE) is in focus after announcing topline results from a rheumatoid-arthritis substudy. This development places immune-mediated disease, clinical evidence, and pipeline sequencing at the forefront of the company's narrative, requiring diligent execution and customer response for long-term relevance. The article emphasizes that the news provides a current reference point for the market to assess how the business manages immune-mediated disease while balancing clinical evidence and pipeline sequencing.

    Kalkine Media•8/26/26•
    Somewhat-Bullish

    Spyre Therapeutics Announces Topline Results from the Rheumatoid Arthritis Sub-study of the SKYWAY Phase 2 Trial of SPY072

    Spyre Therapeutics announced topline results from the rheumatoid arthritis (RA) sub-study of its SKYWAY Phase 2 trial for SPY072. While both doses of SPY072 showed statistically significant benefits compared to placebo in various endpoints and were well-tolerated, the magnitude of effect did not meet the company's target for prioritizing SPY072 as a monotherapy in RA. However, the results support the broader potential of Spyre's TL1A antibodies in autoimmune diseases and as combination components.

    Yahoo Finance Singapore•8/25/26•
    Neutral

    Frequently Asked Questions About SYRE

    Does SYRE pay dividends?
    Spyre Therapeutics Inc. (SYRE) does not currently pay a regular dividend.
    What is SYRE's market cap?
    Spyre Therapeutics Inc. (SYRE) has a market capitalization of $7.85B with a current stock price of $90.36.

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In